IDEAYA Appoints New Chief Development Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy IDYA?
Source: Newsfilter
- Executive Appointment: IDEAYA Biosciences has appointed Dr. Theodora Ross as Chief Development Officer, responsible for leading early clinical development and guiding the long-term R&D strategy for the company's oncology pipeline, which is expected to accelerate the advancement of its clinical assets.
- Extensive Experience: Dr. Ross brings over 30 years of oncology experience, having served as Vice President at AbbVie where she successfully advanced five early clinical programs to Phase 1/2 trials, demonstrating her exceptional capabilities in clinical execution and pipeline strategy.
- Strategic Impact: The addition of Dr. Ross is seen as a significant step for IDEAYA in advancing its innovative oncology pipeline, expected to enhance the company's R&D strength and market competitiveness, solidifying its leadership position in precision medicine.
- Company Vision: IDEAYA is committed to developing transformative therapies for cancer, and Dr. Ross's appointment will further drive the development of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs), aiming to improve clinical outcomes for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 31.450
Low
30.00
Averages
49.86
High
79.00
Current: 31.450
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Biosciences Initiates Phase 1 Clinical Trial for IDE849 and IDE161
- Trial Launch: IDEAYA Biosciences has announced the initiation of a Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in DLL3 upregulated solid tumors, marking a significant advancement in the field of precision medicine.
- Global Multi-Site Study: The clinical trial will enroll patients across North America, Europe, Australia, South America, and Asia, utilizing a 3.5 mg/kg IV dose every three weeks for dose escalation, expected to provide new treatment options for patients worldwide.
- Efficacy Observations: Among four small cell lung cancer patients pre-treated with IMDELLTRA®, three partial responses were observed, indicating the potential efficacy of IDE849 and further validating its prospects in clinical applications.
- Innovative Mechanism: The combination of IDE161, a first-in-class PARG inhibitor, with IDE849 aims to enhance anti-tumor activity by increasing the accumulation of TOP1 cleavage complexes, potentially delivering more durable efficacy for IDEAYA's ADC pipeline.
See More
IDEAYA Biosciences Advances Clinical Trials for IDE849 and IDE161
- Clinical Trial Progress: IDEAYA Biosciences has announced the initiation of its Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in tumors such as small cell lung cancer, showcasing the company's ongoing innovation in precision medicine.
- Dose Evaluation: Currently, IDE849 is being assessed at a dose of 3.5 mg/kg, with an expansion cohort at 2.4 mg/kg showing 3 partial responses out of 4 small cell lung cancer patients, indicating the drug's potential efficacy and tolerability in treatment.
- Global Recruitment Plan: The clinical trial will recruit patients across multiple regions including North America, Europe, Australia, South America, and Asia, reflecting IDEAYA's strategic intent to expand its clinical research globally to meet diverse medical needs.
- Combination Therapy Outlook: The combination of IDE161 as a PARG inhibitor with IDE849 is expected to enhance efficacy by increasing the accumulation of TOP1 lesions, further solidifying IDEAYA's leading position in the development of anti-tumor drugs, particularly in areas with significant unmet medical needs.
See More
IDEAYA Grants 49,000 Stock Options to New Employees
- Options Granted: IDEAYA Biosciences granted a total of 49,000 non-qualified stock options to two newly hired employees on March 26, 2026, highlighting the company's commitment to attracting talent.
- Incentive Plan Context: The stock options were awarded under the IDEAYA 2023 Employment Inducement Incentive Award Plan, designed to entice individuals who were not previously employed by IDEAYA, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $32.09 per share, matching the closing price of IDEAYA's common stock on the grant date, aligning employee interests with the company's stock performance.
- Vesting Schedule: The options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, ensuring ongoing employee contributions during their tenure at IDEAYA.
See More
IDEAYA Grants Stock Options to New Employees
- Stock Options Granted: On March 26, 2026, IDEAYA Biosciences granted 49,000 non-qualified stock options to two new employees, aimed at attracting top talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Incentive Plan Context: The stock options were awarded under the 2023 Employment Inducement Incentive Award Plan, which is exclusively for granting equity awards to new hires or individuals returning after a bona fide non-employment period, highlighting the company's commitment to talent acquisition.
- Exercise Price: The granted stock options have an exercise price of $32.09 per share, matching the closing price of IDEAYA's common stock on the Nasdaq Global Select Market on the grant date, aligning employee interests with company performance.
- Vesting Schedule: These stock options have a 10-year term with a four-year vesting schedule, where 25% vests on the first anniversary of the vesting commencement date and the remaining 75% vests in equal monthly installments over the next three years, ensuring continued employee service to IDEAYA for vesting eligibility.
See More
IDEAYA Biosciences Delays Data Release for Eye Cancer Trial
- Data Release Delay: IDEAYA Biosciences announced a delay in the release of topline results from its phase 2/3 trial of darovasertib for first-line metastatic uveal melanoma, now expected in early April instead of the last week of March, which may impact investor confidence.
- Database Lock Timing: The database lock for the OptimUM-02 trial is now scheduled for the first half of April, and this change in timeline could create uncertainty in market expectations regarding the company's future data outcomes, although analysts express limited concern.
- Analyst Rating Maintained: Mizuho analyst Graig Suvannavejh maintains an outperform rating on IDEAYA with a price target of $46, indicating approximately 40% upside potential, reflecting confidence in the company's long-term prospects despite the delay.
- Financial Performance Beats Expectations: IDEAYA recently reported a GAAP EPS of -$0.94, beating estimates by $0.03, and revenue of $10.88 million, exceeding expectations by $4.93 million, indicating the company still demonstrates resilience in its financial performance.
See More
IDEAYA Biosciences Announces Upcoming Investor Relations Events
- Clinical Data Release: IDEAYA Biosciences is set to present topline data from its Phase 2/3 OptimUM-02 trial for HLA-A2*-negative metastatic uveal melanoma at the Bank of America Merrill Lynch Health Care Conference on May 12 and the Stifel 2026 Targeted Oncology Virtual Forum on May 19, marking a significant advancement in the precision oncology sector.
- Investor Relations Activities: The company will host live webcasts to update investors and analysts on its clinical trial progress, with the events accessible via the 'Investors/Events' section of the IDEAYA website, which is expected to enhance the company's visibility in the capital markets.
- Technological Integration Advantage: IDEAYA's focus on integrating small-molecule drug discovery, structural biology, and bioinformatics underscores its robust capabilities in developing personalized cancer therapies, potentially attracting greater investor interest in its innovative approaches.
- Forward-Looking Statement Risks: The company cautions that various risks and uncertainties related to the timing, progress, and results of clinical trials could lead to significant discrepancies between actual outcomes and expectations, which is crucial information for investor decision-making.
See More
IDEAYA Biosciences Initiates Phase 1 Clinical Trial for IDE849 and IDE161
- Trial Launch: IDEAYA Biosciences has announced the initiation of a Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in DLL3 upregulated solid tumors, marking a significant advancement in the field of precision medicine.
- Global Multi-Site Study: The clinical trial will enroll patients across North America, Europe, Australia, South America, and Asia, utilizing a 3.5 mg/kg IV dose every three weeks for dose escalation, expected to provide new treatment options for patients worldwide.
- Efficacy Observations: Among four small cell lung cancer patients pre-treated with IMDELLTRA®, three partial responses were observed, indicating the potential efficacy of IDE849 and further validating its prospects in clinical applications.
- Innovative Mechanism: The combination of IDE161, a first-in-class PARG inhibitor, with IDE849 aims to enhance anti-tumor activity by increasing the accumulation of TOP1 cleavage complexes, potentially delivering more durable efficacy for IDEAYA's ADC pipeline.
See More
IDEAYA Biosciences Advances Clinical Trials for IDE849 and IDE161
- Clinical Trial Progress: IDEAYA Biosciences has announced the initiation of its Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in tumors such as small cell lung cancer, showcasing the company's ongoing innovation in precision medicine.
- Dose Evaluation: Currently, IDE849 is being assessed at a dose of 3.5 mg/kg, with an expansion cohort at 2.4 mg/kg showing 3 partial responses out of 4 small cell lung cancer patients, indicating the drug's potential efficacy and tolerability in treatment.
- Global Recruitment Plan: The clinical trial will recruit patients across multiple regions including North America, Europe, Australia, South America, and Asia, reflecting IDEAYA's strategic intent to expand its clinical research globally to meet diverse medical needs.
- Combination Therapy Outlook: The combination of IDE161 as a PARG inhibitor with IDE849 is expected to enhance efficacy by increasing the accumulation of TOP1 lesions, further solidifying IDEAYA's leading position in the development of anti-tumor drugs, particularly in areas with significant unmet medical needs.
See More
IDEAYA Grants 49,000 Stock Options to New Employees
- Options Granted: IDEAYA Biosciences granted a total of 49,000 non-qualified stock options to two newly hired employees on March 26, 2026, highlighting the company's commitment to attracting talent.
- Incentive Plan Context: The stock options were awarded under the IDEAYA 2023 Employment Inducement Incentive Award Plan, designed to entice individuals who were not previously employed by IDEAYA, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $32.09 per share, matching the closing price of IDEAYA's common stock on the grant date, aligning employee interests with the company's stock performance.
- Vesting Schedule: The options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, ensuring ongoing employee contributions during their tenure at IDEAYA.
See More
IDEAYA Grants Stock Options to New Employees
- Stock Options Granted: On March 26, 2026, IDEAYA Biosciences granted 49,000 non-qualified stock options to two new employees, aimed at attracting top talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Incentive Plan Context: The stock options were awarded under the 2023 Employment Inducement Incentive Award Plan, which is exclusively for granting equity awards to new hires or individuals returning after a bona fide non-employment period, highlighting the company's commitment to talent acquisition.
- Exercise Price: The granted stock options have an exercise price of $32.09 per share, matching the closing price of IDEAYA's common stock on the Nasdaq Global Select Market on the grant date, aligning employee interests with company performance.
- Vesting Schedule: These stock options have a 10-year term with a four-year vesting schedule, where 25% vests on the first anniversary of the vesting commencement date and the remaining 75% vests in equal monthly installments over the next three years, ensuring continued employee service to IDEAYA for vesting eligibility.
See More
IDEAYA Biosciences Delays Data Release for Eye Cancer Trial
- Data Release Delay: IDEAYA Biosciences announced a delay in the release of topline results from its phase 2/3 trial of darovasertib for first-line metastatic uveal melanoma, now expected in early April instead of the last week of March, which may impact investor confidence.
- Database Lock Timing: The database lock for the OptimUM-02 trial is now scheduled for the first half of April, and this change in timeline could create uncertainty in market expectations regarding the company's future data outcomes, although analysts express limited concern.
- Analyst Rating Maintained: Mizuho analyst Graig Suvannavejh maintains an outperform rating on IDEAYA with a price target of $46, indicating approximately 40% upside potential, reflecting confidence in the company's long-term prospects despite the delay.
- Financial Performance Beats Expectations: IDEAYA recently reported a GAAP EPS of -$0.94, beating estimates by $0.03, and revenue of $10.88 million, exceeding expectations by $4.93 million, indicating the company still demonstrates resilience in its financial performance.
See More
IDEAYA Biosciences Announces Upcoming Investor Relations Events
- Clinical Data Release: IDEAYA Biosciences is set to present topline data from its Phase 2/3 OptimUM-02 trial for HLA-A2*-negative metastatic uveal melanoma at the Bank of America Merrill Lynch Health Care Conference on May 12 and the Stifel 2026 Targeted Oncology Virtual Forum on May 19, marking a significant advancement in the precision oncology sector.
- Investor Relations Activities: The company will host live webcasts to update investors and analysts on its clinical trial progress, with the events accessible via the 'Investors/Events' section of the IDEAYA website, which is expected to enhance the company's visibility in the capital markets.
- Technological Integration Advantage: IDEAYA's focus on integrating small-molecule drug discovery, structural biology, and bioinformatics underscores its robust capabilities in developing personalized cancer therapies, potentially attracting greater investor interest in its innovative approaches.
- Forward-Looking Statement Risks: The company cautions that various risks and uncertainties related to the timing, progress, and results of clinical trials could lead to significant discrepancies between actual outcomes and expectations, which is crucial information for investor decision-making.
See More
